Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Quinaprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50 = 0.06 nM) and an active metabolite of the ACE inhibitor prodrug quinapril (Item No. 21439).1,2 It inhibits calcium overload and rod to round cell shape change induced by lysophosphatidylcholine (LPC) in isolated rat cardiomyocytes when used at concentrations of 20 and 50 µM.2 Quinaprilat (3 µg/kg) reduces the frequency of ventricular fibrillation in a dog model of myocardial ischemia and reperfusion injury.3 It also reduces blood pressure and proteinuria in rat models of uranyl nitrate- or 5/6 nephrectomy-induced chronic renal failure when administered at a dose of 0.1 mg/kg.4
WARNING This product is not for human or veterinary use.
1. Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme. Eur. J. Pharmacol. 266(3), 201-211 (1994).
2. Protective effect of quinaprilat, an active metabolite of quinapril, on Ca2+-
3. Electrophysiologic effects of quinaprilat in dogs during acute myocardial ischemia and following reperfusion. Coron. Artery Dis. 9(10), 697-701 (1998).
4. Effects of a therapy with losartan and quinaprilat on the progression of chronic renal failure in rats after a single dose of uranyl nitrate or 5/6 nephrectomy. Exp. Toxicol. Pathol. 54(5-6), 359-366 (2003).